Cantor Fitzgerald Estimates KROS FY2025 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Keros Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings per share of ($5.82) for the year. Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company’s revenue was up 4750.0% compared to the same quarter last year. During the same period last year, the firm earned ($1.33) earnings per share.

KROS has been the topic of several other reports. Piper Sandler dropped their target price on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, January 17th. HC Wainwright decreased their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a report on Friday, December 13th. Scotiabank reduced their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research report on Thursday, January 16th. Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Finally, William Blair lowered Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $52.56.

Keros Therapeutics Trading Up 5.5 %

KROS opened at $12.02 on Wednesday. Keros Therapeutics has a twelve month low of $9.77 and a twelve month high of $73.00. The firm has a market cap of $486.93 million, a price-to-earnings ratio of -2.31 and a beta of 1.43. The company has a fifty day simple moving average of $33.12 and a 200 day simple moving average of $46.51.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares during the last quarter. KBC Group NV grew its position in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after acquiring an additional 432 shares during the period. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Keros Therapeutics by 36.7% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock worth $223,000 after buying an additional 1,033 shares during the period. Algert Global LLC lifted its holdings in shares of Keros Therapeutics by 10.6% during the second quarter. Algert Global LLC now owns 15,700 shares of the company’s stock worth $717,000 after buying an additional 1,505 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Keros Therapeutics in the third quarter valued at about $89,000. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.